Regulatory requirements, due diligence obligations, and credit committee review standards for Certified Development Companies
Certified Development Companies carry regulatory obligations regarding feasibility studies that go beyond what 7(a) lenders face. The CDC is not simply a pass-through entity that packages 504 applications. Under SOP 50 10 8 and NADCO (National Association of Development Companies) best practices, the CDC bears specific analytical responsibilities, including the requirement to address property classification in its credit memorandum, the obligation to perform independent due diligence on the borrower's projections, and accountability for the quality of the underwriting package submitted to the SBA processing center.
This guide is written for CDC credit officers, underwriters, and credit committee members who review feasibility studies as part of the 504 loan approval process. It covers the regulatory framework, the CDC's specific obligations, how to scope a feasibility study engagement, and a review checklist designed for CDC credit committee use.
The CDC's feasibility study obligations derive from three sources: SOP 50 10 8, the CDC's own operating policies, and NADCO guidance. Understanding how these three layers interact is essential for compliance.
| Source | Requirement | Practical Implication |
|---|---|---|
| SOP 50 10 8, Chapter 4 | CDC credit memorandum must address whether the project property is a limited or special purpose property | The CDC must reach a classification conclusion and document its reasoning. Cannot defer to the first mortgage lender or omit the analysis. |
| SOP 50 10 8, Chapter 4 | CDC must perform independent analysis of repayment ability | The CDC cannot simply adopt the borrower's projections. Must demonstrate independent evaluation of revenue and expense assumptions. |
| SOP 50 10 8, Appendix 3 | Defines special purpose property types and associated equity injection tiers | The CDC must apply the correct equity structure (50/40/10, 50/35/15, or 50/30/20) based on the classification. Errors affect loan structure. |
| 13 CFR § 120.910 | Establishes 504 equity injection requirements by project type | Regulatory basis for the tiered equity structure. CDC must verify compliance. |
| 13 CFR § 120.823 | CDCs must maintain adequate professional staff with lending and servicing experience | The CDC's review of the feasibility study must be conducted by qualified staff, not rubber-stamped. |
| NADCO best practices | Recommends independent third-party feasibility studies for special purpose properties, startups, and new construction | While not regulatory, NADCO guidance reflects industry consensus and is referenced by SBA examiners during CDC reviews. |
| CDC operating policies | Individual CDC credit policies may impose additional requirements | Many CDCs require feasibility studies for all loans above a certain threshold or for specific property types, beyond SBA minimums. |
The CDC's liability exposure regarding feasibility studies operates on two levels: pre-approval compliance and post-close examiner scrutiny.
Pre-approval. The SBA processing center reviews the complete 504 application package, including the CDC's credit memorandum and any supporting feasibility study. If the processing center analyst determines that the credit memo's property classification is incorrect, the projections are unsupported, or the feasibility analysis is deficient, the application will be returned for correction or denied. This delays the loan (typically 2 to 6 weeks for revision cycles) and reflects poorly on the CDC's underwriting quality in the SBA's internal tracking.
Post-close examiner review. SBA examiners periodically review CDC portfolios and individual loan files. If an examiner determines that a CDC approved a 504 loan without adequate feasibility analysis (for example, approving a startup hotel at the 10% equity tier when the property should have been classified as special purpose at 15%), the consequences can include corrective action requirements, increased monitoring, and in severe cases, impact on the CDC's operating authority. A well-documented feasibility study in the file provides the CDC with a defensible record of prudent underwriting.
The "independent analysis" obligation. The SOP requires CDCs to perform independent analysis of repayment ability. This does not mean the CDC must prepare its own feasibility study. It means the CDC must critically evaluate whatever feasibility analysis is presented, reach its own conclusion about the project's viability, and document that conclusion in the credit memorandum. Accepting a third-party feasibility study at face value without independent evaluation does not satisfy this obligation.
CDCs can influence the quality of the feasibility study before it is prepared by providing clear scope guidance to the analyst. The following framework ensures the study will meet both the CDC's credit committee standards and the SBA processing center's expectations.
| Scope Element | CDC Should Specify | Why It Matters |
|---|---|---|
| Property classification analysis | Request explicit special purpose vs multipurpose determination with SOP 50 10 8 Appendix 3 reference | Directly determines equity tier. If the study does not address classification, the CDC must do it independently. |
| DSCR threshold | Specify the CDC's minimum DSCR requirement (typically 1.20x to 1.25x) | The SBA has no codified 504 DSCR minimum. Each CDC sets its own. The analyst must know the target. |
| Projection period | 3 to 5 years, with monthly detail for Year 1 | Monthly Year 1 detail is essential for new construction and startup projects where ramp-up timing affects DSCR. |
| Sensitivity analysis | Require base, optimistic, and pessimistic scenarios with DSCR calculated for each | The pessimistic scenario should show where DSCR drops below the CDC's minimum. If it doesn't, stress testing is insufficient. |
| Owner-occupancy validation | Request confirmation that the borrower's operations meet the 51% (existing) or 60% (new construction) threshold | 504-specific requirement. The feasibility study should address this if the property has any non-owner-occupied component. |
| Reliance letter addressees | Specify that the reliance letter must be addressed to the CDC, the first mortgage lender, and the SBA | A reliance letter addressed only to the borrower does not permit the CDC or SBA to rely on the analysis. |
| Data recency | Require that market data be no more than 6 months old at the time of the study | Stale data undermines the analysis. Processing center analysts check data dates. |
| Site visit requirement | Require a documented site visit with photographs for projects above $500,000 | Desktop-only studies miss critical information. Site visit evidence strengthens the CDC's credit memo. |
Timing guidance. The feasibility study should be completed before the CDC finalizes its credit memorandum, not after. The study informs the credit memo's analysis, including the property classification conclusion, the repayment ability assessment, and the risk evaluation. A credit memo written before the feasibility study is available, then amended after the fact, is less defensible during examiner review than one that incorporates the study's findings from the outset.
The National Association of Development Companies (NADCO) publishes best practice guidance for CDC operations. While NADCO guidance is not regulatory (it does not have the force of law), SBA examiners reference it as the industry standard, and CDCs that deviate from NADCO best practices face questions during examinations.
Relevant NADCO guidance for feasibility studies includes the recommendation that CDCs obtain independent third-party feasibility studies for all 504 transactions involving special purpose properties, all startup borrowers, all new construction projects, and any transaction where the CDC's credit committee lacks sufficient expertise to independently evaluate the business model. NADCO also recommends that CDCs maintain a list of qualified feasibility study providers with demonstrated SBA experience, rather than accepting studies from providers the borrower selects without CDC input.
CDC provider management. NADCO best practices suggest that CDCs should maintain an approved provider list based on documented criteria: professional credentials, SBA program experience, property-type specialization, and track record of acceptance by SBA processing centers. This does not mean the CDC must engage the analyst directly (the borrower typically pays for and commissions the study), but the CDC should have confidence that the selected provider will produce work that meets CDC and SBA standards.
The following checklist is designed for CDC credit committee members reviewing a feasibility study as part of a 504 loan approval package. Each item should be evaluated as satisfactory, needs clarification, or deficient.
| # | Review Item | What the Committee Should Confirm |
|---|---|---|
| 1 | Provider independence | No financial relationship between analyst and borrower beyond the study fee. Fee is fixed, not contingent on outcome. |
| 2 | Property classification | Study explicitly addresses special purpose vs multipurpose. Conclusion aligns with SOP 50 10 8 Appendix 3. CDC agrees with classification. |
| 3 | Equity injection tier | Classification supports the equity structure in the 504 application (10%, 15%, or 20%). Any discrepancy must be resolved before approval. |
| 4 | DSCR at CDC threshold | Projected DSCR meets or exceeds the CDC's minimum under the base case scenario. Timeline to achieve DSCR is within two years. |
| 5 | Pessimistic scenario DSCR | Pessimistic case DSCR identified. Committee understands the downside risk and the variables that drive it. |
| 6 | Owner-occupancy compliance | Study confirms borrower's operations meet 51% (existing) or 60% (new construction) occupancy threshold. |
| 7 | Market data recency | Core market data (demographics, competitive inventory, comparable performance) is less than 6 months old. |
| 8 | Competitive supply pipeline | Planned, permitted, and under-construction competitive supply is identified and incorporated into demand projections. |
| 9 | Revenue projection independence | Projections are built from market data, not adopted from the borrower's business plan. Methodology is documented. |
| 10 | Reliance letter scope | Letter addressed to CDC, first mortgage lender, and SBA. Permits reliance for underwriting and compliance purposes. |
| 11 | Site visit documentation | Analyst conducted an in-person site visit. Photos of subject site and key competitors included. |
| 12 | Consistency with credit memo | The credit memo's analysis is consistent with the feasibility study's findings. Any divergence is explained and documented. |
Scoring guidance: all 12 items should be satisfactory before the credit committee approves the loan. Items 2, 3, 4, and 10 (property classification, equity tier, DSCR, reliance letter) are threshold items. If any of these four is deficient, the loan should not proceed until the deficiency is resolved. Items marked "needs clarification" should be resolved through supplemental information from the analyst before the loan is submitted to the SBA processing center.
The CDC credit memorandum is the document where the feasibility study's findings are translated into the CDC's credit decision. The memo should reference the feasibility study by name, date, and author, and incorporate its findings into the following sections.
Property description and classification. State the property type, reference the feasibility study's classification analysis, and document the CDC's concurrence or disagreement. If the CDC agrees with the study's special purpose classification, cite the specific SOP Appendix 3 property type. If the CDC disagrees, document the reasoning. This section directly determines the equity injection tier.
Repayment ability analysis. Reference the feasibility study's DSCR projections under base and pessimistic scenarios. State whether the projected DSCR meets the CDC's minimum requirement. Identify the key assumptions that drive the DSCR and note any assumptions the CDC considers aggressive or conservative relative to its own experience. This is where the CDC demonstrates independent analysis rather than passive adoption of the study's conclusions.
Market and competitive assessment. Summarize the feasibility study's market findings: demand indicators, competitive landscape, and supply pipeline. Note any market risks identified in the study that could affect long-term loan performance. For 504 loans with 20 or 25-year debentures, the long-term market outlook is especially relevant.
Risk factors and mitigants. Document the risks identified in the feasibility study's sensitivity analysis and the factors that mitigate those risks. This section demonstrates to the SBA processing center that the CDC has considered the downside scenarios and made a considered credit decision, not simply approved a loan because the base case DSCR exceeds the minimum.
SBA examiner findings and processing center feedback reveal recurring compliance errors in how CDCs handle feasibility studies. Avoiding these errors strengthens the CDC's underwriting quality and reduces processing delays.
Omitting the classification analysis entirely. Some CDC credit memos describe the property but never state whether it is special purpose or multipurpose. This is a direct SOP violation. The classification must be addressed explicitly.
Applying the wrong equity tier. A CDC that classifies a property as special purpose but structures the loan at the 10% (standard) equity tier has a structural error that the SBA processing center will catch. The classification and the equity tier must be consistent.
Accepting the borrower's projections without independent validation. A credit memo that states "the borrower projects $1.5 million in Year 1 revenue" without any independent market validation does not satisfy the SOP's independent analysis requirement. The feasibility study provides that independent validation.
Failing to address pipeline supply. A credit memo that references "strong market demand" without addressing planned competitive supply additions creates a gap that processing center analysts will question. The feasibility study should address pipeline supply, and the credit memo should reference those findings.
Reliance letter deficiency. A feasibility study with a reliance letter addressed only to the borrower does not provide the CDC or SBA with standing to rely on the analysis. The CDC should confirm the reliance letter's scope before accepting the study.
CDCs that establish relationships with qualified feasibility study providers benefit from more consistent quality, faster turnaround, and fewer revision cycles. When evaluating providers, CDCs should consider Appraisal Institute affiliation (MAI, AI-GRS, Practicing Affiliate), demonstrated 504 program experience (ask for a list of CDCs they have worked with), property-type specialization relevant to the CDC's market, track record of acceptance by SBA processing centers, and the provider's willingness to work within the CDC's scope framework.
For a comprehensive framework for evaluating feasibility study quality, see our lender's guide to evaluating third-party feasibility studies. For details on how 504 feasibility requirements differ from 7(a), see our 504 feasibility study guide.
We work with CDCs nationwide and understand the dual-review process. Our feasibility studies are scoped to satisfy both CDC credit committee standards and SBA processing center expectations. If you are a CDC seeking a qualified feasibility study provider for your 504 pipeline, contact us to discuss a partnership framework.
Contact Us